Form 4: Twist Bioscience CLO Acquires 29,518 PSUs

Twist Bioscience's Senior Vice President, Chief Legal Officer & Corporate Secretary, Dennis Cho, acquired 29,518 Performance Stock Units.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, acquired 29,518 shares of common stock.
• The acquisition occurred on October 28, 2025, at a price of $0 per share.
• These shares represent Performance Stock Units (PSUs) where target criteria were met on the transaction date.
• Following this transaction, Dennis Cho beneficially owns 128,228 shares directly.
• 60% of the acquired PSUs are subject to time-based vesting and will vest on October 1, 2026, contingent on continued service or accelerated vesting as per the award agreement.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of Performance Stock Units by a key executive, especially when performance criteria are met, generally signals positive internal confidence and alignment of interests. While not a direct cash investment, it reflects successful achievement of internal goals and future commitment.

Positives

• The acquisition of Performance Stock Units by a key executive indicates alignment of management interests with shareholder value.
• The meeting of target criteria for PSUs suggests the company achieved specific performance goals, which is a positive operational indicator.

Future Outlook

A significant portion (60%) of the acquired Performance Stock Units are subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on the executive's continued service.

Industry Context

Insider acquisitions of Performance Stock Units are common in the biotechnology sector, often used to incentivize executives based on achieving specific company performance milestones. This transaction reflects a standard compensation practice and can be viewed as a sign of executive confidence in the company's future performance.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) as executive compensation is a common practice across the biotechnology and broader technology sectors, aligning executive incentives with long-term company performance.
• The vesting schedule, with a portion vesting at a future date, is typical for such awards, ensuring retention and continued performance focus.
• The $0 acquisition price is standard for equity awards like PSUs, distinguishing them from open market purchases.

Stakeholder Impact

• Shareholders: The acquisition of PSUs by a senior executive can be viewed positively as it aligns management's interests with long-term shareholder value and indicates confidence in the company's ability to meet performance targets.
• Employees: The vesting of PSUs based on performance criteria and continued service can serve as a positive example of executive incentive structures within the company.

Next Steps

• 60% of the acquired Performance Stock Units will vest on October 1, 2026, subject to Dennis Cho's continued service to Twist Bioscience Corporation.

Key Dates

Recommendation

While the acquisition of Performance Stock Units by a key executive is a positive signal of internal confidence and alignment, it is a routine compensation event rather than a direct open-market purchase. It reinforces a 'hold' stance for existing investors, suggesting stability and continued executive commitment, but does not present new fundamental information that would warrant a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Twist Bioscience, TWST, SEC Form 4, Insider Transaction, Performance Stock Units, PSUs, Executive Compensation, Dennis Cho, Stock Acquisition, Biotechnology